SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-021186
Filing Date
2023-07-31
Accepted
2023-07-31 16:43:36
Documents
14
Period of Report
2023-07-25
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sabs20230728_8k.htm   iXBRL 8-K 30908
2 EXHIBIT 16.1 - LETTER FROM MAYER HOFFMAN MCCANN P.C. TO THE SECURITIES AND EXCHA ex_550342.htm EX-16.1 2737
  Complete submission text file 0001437749-23-021186.txt   189141

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sabs-20230725.xsd EX-101.SCH 3991
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sabs-20230725_def.xml EX-101.DEF 13973
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sabs-20230725_lab.xml EX-101.LAB 18508
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sabs-20230725_pre.xml EX-101.PRE 14005
8 EXTRACTED XBRL INSTANCE DOCUMENT sabs20230728_8k_htm.xml XML 4812
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 231127928
SIC: 2836 Biological Products, (No Diagnostic Substances)